Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|August 3, 2020

MilliporeSigma Invests $20 Million in New Switzerland Laboratory

The investment will allow for the expansion of analytical R&D efforts and will support the company’s reference materials business.

MilliporeSigma plans to build a new, $20-million laboratory facility in Buchs, Switzerland, to support its rapidly growing reference materials business, the company announced in a July 15, 2020 press release. The company anticipates that about two dozen jobs will be created with this expansion.

The three-story, 12,000-ft2 Buchs building is scheduled to be done by December 2021, and the move to the facility is planned for early 2022. The facility will include laboratory and office space aimed at fostering a collaborative environment. The new facility will offer a more efficient working environment for current and future employees in R&D, analytical production, and quality control. The laboratory area can be adapted to new requirements in the future, including increased site capacity.

"Researchers in testing labs around the world use MilliporeSigma’s reference materials every day to help generate accurate, reliable analytical results in pharmaceutical, environmental, and food and beverage analysis,” said Jean-Charles Wirth, head of Applied Solutions at MilliporeSigma, in the company press release. “This new laboratory will allow us to continue to drive innovation in diagnostics and testing and expand our research and development of analytical standards.”

Source: MilliporeSigma


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.